FI111050B - Keskushermoston pesäkekovettumatauti-aivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin valmistusmenetelmä - Google Patents

Keskushermoston pesäkekovettumatauti-aivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin valmistusmenetelmä Download PDF

Info

Publication number
FI111050B
FI111050B FI941860A FI941860A FI111050B FI 111050 B FI111050 B FI 111050B FI 941860 A FI941860 A FI 941860A FI 941860 A FI941860 A FI 941860A FI 111050 B FI111050 B FI 111050B
Authority
FI
Finland
Prior art keywords
mbp
peptide
seq
amino acid
cys
Prior art date
Application number
FI941860A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI941860A0 (fi
FI941860A (fi
Inventor
Kenneth G Warren
Ingrid Catz
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Publication of FI941860A0 publication Critical patent/FI941860A0/fi
Publication of FI941860A publication Critical patent/FI941860A/fi
Application granted granted Critical
Publication of FI111050B publication Critical patent/FI111050B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI941860A 1991-10-22 1994-04-21 Keskushermoston pesäkekovettumatauti-aivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin valmistusmenetelmä FI111050B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2053799 1991-10-22
CA002053799A CA2053799C (en) 1991-10-22 1991-10-22 Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
CA9200448 1992-10-15
PCT/CA1992/000448 WO1993008212A1 (en) 1991-10-22 1992-10-15 Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid

Publications (3)

Publication Number Publication Date
FI941860A0 FI941860A0 (fi) 1994-04-21
FI941860A FI941860A (fi) 1994-04-21
FI111050B true FI111050B (fi) 2003-05-30

Family

ID=4148603

Family Applications (1)

Application Number Title Priority Date Filing Date
FI941860A FI111050B (fi) 1991-10-22 1994-04-21 Keskushermoston pesäkekovettumatauti-aivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin valmistusmenetelmä

Country Status (12)

Country Link
EP (1) EP0610446B1 (no)
AT (1) ATE236193T1 (no)
AU (1) AU2750092A (no)
CA (1) CA2053799C (no)
DE (1) DE69232987T2 (no)
DK (1) DK0610446T3 (no)
ES (1) ES2196007T3 (no)
FI (1) FI111050B (no)
NO (1) NO310513B1 (no)
NZ (1) NZ244807A (no)
RU (1) RU2121850C1 (no)
WO (1) WO1993008212A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
HUT77047A (hu) * 1994-10-25 1998-03-02 Immulogic Pharmaceutical Corporation Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
AU721898B2 (en) * 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
WO1996028470A2 (en) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
WO2005009455A1 (fr) * 2003-07-29 2005-02-03 Terentiev Alexandr Alexandrovi Composition de peptides presentant une propriete immunoregulatrice
AU2009354040A1 (en) * 2009-10-12 2012-05-31 Lifebio Laboratories Llc Composition for treatment of Multiple Sclerosis
US9326773B2 (en) 2012-01-26 2016-05-03 Covidien Lp Surgical device including buttress material
WO2024094562A1 (en) * 2022-11-01 2024-05-10 Universität Zürich Novel mbp peptides and their use in the treatment of multiple sclerosis

Also Published As

Publication number Publication date
DE69232987T2 (de) 2004-01-29
ES2196007T3 (es) 2003-12-16
DK0610446T3 (da) 2003-07-14
EP0610446B1 (en) 2003-04-02
NZ244807A (en) 1997-08-22
CA2053799C (en) 2002-03-12
NO310513B1 (no) 2001-07-16
ATE236193T1 (de) 2003-04-15
CA2053799A1 (en) 1993-04-23
NO941415D0 (no) 1994-04-19
AU2750092A (en) 1993-05-21
WO1993008212A1 (en) 1993-04-29
DE69232987D1 (de) 2003-05-08
RU2121850C1 (ru) 1998-11-20
FI941860A0 (fi) 1994-04-21
EP0610446A1 (en) 1994-08-17
NO941415L (no) 1994-06-22
FI941860A (fi) 1994-04-21
RU94027578A (ru) 1996-10-20

Similar Documents

Publication Publication Date Title
FI111050B (fi) Keskushermoston pesäkekovettumatauti-aivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin valmistusmenetelmä
FI120308B (fi) Peptidi, joka pystyy neutraloimaan tai muuntamaan myeliinin emäksisen proteiinin vasta-aineen tuoton
FR2795735A1 (fr) Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
US7368429B2 (en) Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
Warren et al. Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
CA2201841C (en) Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US7090982B2 (en) Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US20020111312A1 (en) Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
NZ513065A (en) Peptide fragments of MBP, their pharmaceutical compositions and their use in treating multiple sclerosis